Cryptogenic organizing pneumonia natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
Line 18: Line 18:


===Prognosis===
===Prognosis===
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
*Prognosis is generally good after the treatment with corticosteroids.
*Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
*Fatal outcome of cryptogenic organizing pneumonia is rare.<ref name="pmid26175771">{{cite journal |vauthors=Kim M, Cha SI, Seo H, Shin KM, Lim JK, Kim H, Yoo SS, Lee J, Lee SY, Kim CH, Park JY |title=Predictors of Relapse in Patients with Organizing Pneumonia |journal=Tuberc Respir Dis (Seoul) |volume=78 |issue=3 |pages=190–5 |date=July 2015 |pmid=26175771 |pmc=4499585 |doi=10.4046/trd.2015.78.3.190 |url=}}</ref>
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
*The prognosis varies with the [characteristic] of the tumor; [subtype of disease/malignancy] have the most favorable prognosis.
 
 


==References==
==References==

Revision as of 19:11, 1 March 2018

Cryptogenic Organizing Pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cryptogenic organizing pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Electrocardiogram

Ultrasonography/Echocardiography

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cryptogenic organizing pneumonia natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cryptogenic organizing pneumonia natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cryptogenic organizing pneumonia natural history, complications and prognosis

CDC on Cryptogenic organizing pneumonia natural history, complications and prognosis

Cryptogenic organizing pneumonia natural history, complications and prognosis in the news

Blogs on Cryptogenic organizing pneumonia natural history, complications and prognosis

Directions to Hospitals Treating Cryptogenic organizing pneumonitis

Risk calculators and risk factors for Cryptogenic organizing pneumonia natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Natural History, Complications, and Prognosis

Natural History

  • The symptoms of cryptogenic organizing pneumonia usually develop in the fifth or sixth decade of life and start with symptoms such as a cough, dyspnea, and weight loss.
  • Cryptogenic organizing pneumonia patients have the good prognosis after the course of corticosteroids. Fatal outcome of cryptogenic organizing pneumonia is very rare.

Complications

  • Common complications of [disease name] include:
    • [Complication 1]
    • [Complication 2]
    • [Complication 3]

Prognosis

  • Prognosis is generally good after the treatment with corticosteroids.
  • Fatal outcome of cryptogenic organizing pneumonia is rare.[1]

References

  1. Kim M, Cha SI, Seo H, Shin KM, Lim JK, Kim H, Yoo SS, Lee J, Lee SY, Kim CH, Park JY (July 2015). "Predictors of Relapse in Patients with Organizing Pneumonia". Tuberc Respir Dis (Seoul). 78 (3): 190–5. doi:10.4046/trd.2015.78.3.190. PMC 4499585. PMID 26175771.